JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 4, 2003; DOI: 10.1124/jpet.103.058602


0022-3565/04/3082-547-554$20.00
JPET 308:547-554, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.058602v1
308/2/547    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, C. M.
Right arrow Articles by Selley, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, C. M.
Right arrow Articles by Selley, D. E.

NEUROPHARMACOLOGY

Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at µ- and {delta}-Opioid Receptors

Chad M. Thompson, Heidi Wojno, Elisabeth Greiner, Everette L. May, Kenner C. Rice, and Dana E. Selley

Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies (C.M.T., H.W., E.L.M., D.E.S.), Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia; and Laboratory of Medicinal Chemistry (E.G., K.C.R.), National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450–2D6, which catalyzes O-demethylation of codeine to morphine. However, O-demethylation reportedly is not required for analgesic activity of the 7,8-saturated codeine congeners dihydrocodeine, hydrocodone, and oxycodone. This study determined the potency and efficacy of these compounds and their demethylated derivatives to stimulate µ- and {delta}-opioid receptor-mediated G-protein activation using agonist-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTP{gamma}S) binding. Results showed that 7,8-saturated codeine congeners were more efficacious than codeine in activating µ-receptors, but only dihydrocodeine was more efficacious at {delta}-receptors. Hydrocodone and oxycodone were ~10-fold more potent than codeine and dihydrocodeine at either receptor. Morphine-like compounds with a 3-hydroxy group were ~30- to 100-fold more potent than their 3-methoxy analogs at the µ-receptor, and these compounds generally exhibited greater efficacy (e.g., morphine produced 2-fold greater maximal stimulation than codeine). Removal of the N-methyl group did not affect efficacy or potency of codeine congeners to activate µ-receptors, whereas this modification generally increased efficacy but decreased potency of morphine congeners. At the {delta} receptor, morphine congeners showed greater potency and structure-dependent differences in efficacy compared with codeine congeners, whereas removal of the N-methyl group had effects similar to those observed at the µ-receptor. These results demonstrate that 7,8-saturated codeine congeners are more efficacious than codeine, which may explain their lack of requirement for 3-O-demethylation in vivo. Nonetheless, because all 7,8-saturated codeine congeners were significantly less potent than their morphine derivatives, further research is needed to understand the relationship between metabolism and in vivo activity of these compounds.


Received August 15, 2003; accepted October 29, 2003.

Address correspondence to: Dr. Dana E. Selley, Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Medical College of Virginia, Box 980524, 1112 East Clay Street, Richmond, VA 23298-0524. E-mail: deselley{at}hsc.vcu.edu




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
K. K. Lemberg, A. O. Siiskonen, V. K. Kontinen, J. T. Yli-Kauhaluoma, and E. A. Kalso
Pharmacological Characterization of Noroxymorphone as a New Opioid for Spinal Analgesia
Anesth. Analg., February 1, 2008; 106(2): 463 - 470.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. O. Nikolaev, C. Boettcher, C. Dees, M. Bunemann, M. J. Lohse, and M. H. Zenk
Live Cell Monitoring of {micro}-Opioid Receptor-mediated G-protein Activation Reveals Strong Biological Activity of Close Morphine Biosynthetic Precursors
J. Biol. Chem., September 14, 2007; 282(37): 27126 - 27132.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
K. Lemberg, V. K. Kontinen, K. Viljakka, I. Kylanlahti, J. Yli-Kauhaluoma, and E. Kalso
Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.
Anesth. Analg., June 1, 2006; 102(6): 1768 - 1774.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.